The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?

PLoS Med. 2016 Feb 9;13(2):e1001955. doi: 10.1371/journal.pmed.1001955. eCollection 2016 Feb.

Abstract

Ameet Sarpatwari and Aaron Kesselheim explore whether stripping branded drugs of trademark protection would improve the efficiency and fairness of health care.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Costs and Cost Analysis
  • Drug Costs*
  • Drug Industry / methods*
  • Drugs, Generic*
  • Economic Competition*
  • Humans
  • Patents as Topic / statistics & numerical data*

Substances

  • Drugs, Generic

Grant support

This work was supported in part by the Robert Wood Johnson Foundation’s Public Health Law Research program. ASK is a Greenwall Faculty Scholar in Bioethics and is supported by the Harvard Program in Therapeutic Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.